Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFudan University
About this trial
Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
Eligibility criteria
Qualifiers
Male or female aged 18 and ≤ 75;
Histologically or cytologically confirmed unresectable or metastatic clear cell carcinoma of the kidney, which may contain sarcomatoid lesions;
At least one measurable target lesion at the time of enrollment according to RECIST1.1(Response Evaluation Criteria In Solid Tumors) standards;
Tissue samples are available for testing;
Disqualifiers
Radiation, surgery, chemotherapy, immunotherapy or molecular targeted therapy for tumors
To participate in other clinical studies of drug therapy
Live attenuated vaccine history
Previously received PD-1/PD-L1 monoclonal antibody, CTLA-4 antibody(cytolytic T lymphocyte-associated antigen) or other immunotherapy;
Trial design
Treatments tested in this trial
- Anlotinib, Everolimus and Tislelizumab
Treatment groups
66 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov